ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Carisma Therapeutics raises $53 million for CAR-T alternative using macrophages

by Ryan Cross
July 8, 2018 | APPEARED IN VOLUME 96, ISSUE 28

 

Philadelphia-based Carisma Therapeutics has raised $53 million in series A financing to develop new cancer cell therapies based on research from University of Pennsylvania scientists. Unlike the two commercial CAR-T cancer cell therapies, which use engineered T cells, Carisma’s therapy uses macrophages, a different kind of immune cell that eats other cells through phagocytosis. By adding chimeric antigen receptor (CAR) proteins, Carisma hopes to create macrophages that will chow down on cancer. AbbVie Ventures and HealthCap led the funding.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment